ClinicalTrials.gg
CompletedNCT07218744Updated Jan 7, 2026

Study Assessing the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]-INCB123667 in Healthy Male Participants

A Phase 1 interventional study of INCB123667 in Healthy Participants, sponsored by Incyte Corporation. Completed at 1 site in United States. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-07.

Sponsored by Incyte Corporation · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
9
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

This study will assess the mass balance, pharmacokinetics, and metabolite profiles of a single oral dose of [14C] INCB123667 in healthy male participants.

02

Conditions studied

  • Healthy Participants

Keywords

  • INCB123667
03

In context

Lead sponsor

Incyte Corporation is the lead sponsor of 288 studies on the registry; 34 are open to participants now.

Of its 149 completed or terminated interventional studies of FDA-regulated products, 95 (64%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ability to comprehend and willingness to sign a written ICF for the study.
  • Healthy males age 18 to 55 years, inclusive, at the time of signing the ICF.
  • between 18.0 and 32.0 kg/m2, inclusive, at the time of screening.
  • No findings in screening evaluations (eg, clinical, laboratory, vital signs, ). Tests with results that fail eligibility requirements may be repeated once during screening if the investigator believes the results to be in error.
  • Ability to swallow and retain oral medication.

Exclusion criteria

Exclusion Criteria:

  • History of respiratory, renal, GI, endocrine, hematopoietic, psychiatric, and/or neurological disease.
  • History of cardiovascular, cerebrovascular, peripheral vascular, or thrombotic disease or uncontrolled hypertension (systolic blood pressure > 140 mmHg or diastolic blood pressure > 90 mmHg at screening, confirmed by repeat testing).
  • Presence of a malabsorption syndrome (eg, Crohn's disease or chronic pancreatitis) that could possibly affect drug absorption.
  • Current or recent (≤ 6 months of screening), clinically significant gastrointestinal disease or surgery or any history of GI surgery (including cholecystectomy, excluding appendectomy and uncomplicated hernia repair) that is anticipated to affect the absorption of the study drug.
  • Any major surgery within 6 months (≤ 6 months) of screening.
  • Donation of blood to a blood bank or participation in a clinical study (except a screening visit) within 4 weeks of screening (within 2 weeks for donation of plasma only).
  • Positive test for , , or . Participants whose HBV results are compatible with prior immunization or immunity due to infection may be included at the discretion of the investigator.
  • History of significant alcohol use within 3 months of screening, defined as regular alcohol consumption > 21 units per week for males (1 unit = 0.5 pint of beer or a 25-mL shot of 40% spirit, 1.5 to 2 units = 125 mL glass of wine, depending on type).
  • Positive urine or breath test result for ethanol or positive urine or serum screen for drugs of abuse that are not otherwise explained by permitted concomitant medications or diet.
  • Current treatment or treatments within 30 days or 5 half-lives (whichever is longer) before the first dose of study drug on Day 1 with another medication, or current enrollment in another investigational drug study.
  • Participation in more than 3 radiolabeled drug studies in the last 12 months (previous study in which exposures are known to the investigator to be at least 4 months prior to check-in [Day -1]; previous studies in which exposures are not known to the investigator to be at least 6 months prior to check-in [Day -1]).
  • Exposure to significant diagnostic or therapeutic radiation (eg, serial x-ray, computed tomography scan, barium meal) or employment in a job requiring radiation exposure monitoring within 12 months prior to check-in.
  • Current treatment or treatment within 15 days or 5 half-lives (whichever is longer) before the first dose of study drug with any medications known to be an inducer or potent inhibitor of , BCRP, or P-gp (refer to the Certara Drug Interaction Database Program for prohibited medications).
  • History of tobacco- or nicotine-containing product use within 1 month of screening. However, use of nicotine-containing products that is equivalent to ≤ 2 cigarettes per week may be permitted at the discretion of the investigator.

Other protocol-defined Inclusion/Exclusion Criteria may apply.

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
9 participants (actual)

Study arms

  • Experimental
    Treatment: INCB123667

    Participants will be administered INCB123667 tablet orally, followed approximately 10 minutes later by an oral dose solution of radiolabeled INCB123667.

    Drug: INCB123667

Interventions

  • INCB123667 will be administered orally as a tablet dose, followed approximately 10 minutes later by an oral dose solution of radiolabeled INCB123667.

06

What researchers measure

Primary outcomes

  1. Total Recovery (Urine + Feces) of the Administered Radioactivity

    Radioactivity in urine and feces was reported as the percentage of the administered radioactivity excreted.

    Time frame: Approximately 2 weeks

  2. Percentage of total radioactive dose in Plasma, Urinary and Fecal Excretion

    To characterize the metabolic profile and identify circulating and excreted metabolites of INCB123667 following administration of a single oral dose of INCB123667 followed by an oral dose solution of \[14C\]-INCB123667 using liquid chromatography with mass spectral detection.

    Time frame: Up to approximately 2 months

Secondary outcomes

  1. PK for plasma INCB123667: Cmax

    Defined as the maximum plasma concentration.

    Time frame: Up to approximately 2 months

  2. PK for plasma INCB123667: tmax

    Defined as the time to reach maximum concentration.

    Time frame: Up to approximately 2 months

  3. PK for plasma INCB123667: AUClast

    Defined as area under the concentration-time profile from time zero to time of the last quantifiable concentration (Clast).

    Time frame: Up to approximately 2 months

  4. PK for plasma INCB123667: AUCinf

    Defined as area under the concentration-time profile extrapolated to time of infinity.

    Time frame: Up to approximately 2 months

  5. PK for plasma INCB123667: t½

    Defined as terminal-phase half-life.

    Time frame: Up to approximately 2 months

  6. PK for plasma INCB123667: CL/F

    Defined as apparent clearance.

    Time frame: Up to approximately 2 months

  7. PK for plasma INCB123667: Vz/F

    Defined as apparent volume of distribution.

    Time frame: Up to approximately 2 months

  8. PK for whole blood and plasma total radioactivity: Cmax

    Defined as the maximum plasma concentration.

    Time frame: Up to approximately 2 months

  9. PK for whole blood and plasma total radioactivity: tmax

    Defined as the time to reach maximum concentration.

    Time frame: Up to approximately 2 months

  10. PK for whole blood and plasma total radioactivity: t½

    Defined as terminal-phase half-life.

    Time frame: Up to approximately 2 months

  11. PK for whole blood and plasma total radioactivity: AUClast

    Defined as area under the concentration-time profile from time zero to time of the last quantifiable concentration (Clast).

    Time frame: Up to approximately 2 months

  12. PK for whole blood and plasma total radioactivity: AUCinf

    Defined as area under the concentration-time profile extrapolated to time of infinity.

    Time frame: Up to approximately 2 months

  13. Treatment Emergent Adverse Events (TEAEs)

    Adverse events reported for the first time or worsening of a pre-existing event, occurring after study treatment administration.

    Time frame: Up to approximately 2 months

07

Study locations

1 site
  • Fortrea Clinical Research Unit Ltd Labcorp Clinical Research Unit Limited Madison
    Madison, Wisconsin 53704, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2025 to primary completion in Dec 2025, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 16, 2025
First posted
Oct 20, 2025
StartActual
Nov 13, 2025
Primary completionActual
Dec 10, 2025
CompletionActual
Dec 10, 2025
Last update
Jan 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07218744
Lead sponsor
Incyte Corporation
Responsible party
Sponsor
First posted
Oct 20, 2025
Start date
Nov 13, 2025
Primary completion
Dec 10, 2025
Completion
Dec 10, 2025
Last update
Jan 7, 2026

Study contacts

Incyte Medical Monitor
study director · Incyte Corporation

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CDK2 Inhibitor INCB123667

Start the discussion